As of June 14, 2025, Evelo Biosciences Inc (EVLO) reports a Current Ratio of 4.16.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Evelo Biosciences Inc's Current Ratio
Over recent years, Evelo Biosciences Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2022-12-31 | 4.16 |
| 2021-12-31 | 4.08 |
| 2020-12-31 | 3.59 |
| 2019-12-31 | 8.35 |
| 2018-12-31 | 16.48 |
This slight upward trend highlights how Evelo Biosciences Inc manages its short-term assets and liabilities over time.
Comparing Evelo Biosciences Inc's Current Ratio to Peers
To better understand Evelo Biosciences Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Evelo Biosciences Inc (EVLO) | 4.16 |
| Crinetics Pharmaceuticals Inc (CRNX) | 23.04 |
| IVERIC bio Inc (ISEE) | 18.63 |
| Sesen Bio Inc (SESN) | 17.77 |
| AVROBIO Inc (AVRO) | 15.78 |
| Dyne Therapeutics Inc (DYN) | 15.60 |
Compared to its competitors, Evelo Biosciences Inc's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.